Pfizer Inc. (PFE) Shares Sold by Rational Advisors LLC

Rational Advisors LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 68.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 6,806 shares of the biopharmaceutical company’s stock after selling 14,664 shares during the period. Rational Advisors LLC’s holdings in Pfizer were worth $246,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ballew Advisors Inc bought a new stake in Pfizer in the first quarter worth $102,000. W.G. Shaheen & Associates DBA Whitney & Co bought a new stake in Pfizer in the first quarter worth $132,000. Bray Capital Advisors bought a new stake in Pfizer in the first quarter worth $139,000. Braun Bostich & Associates Inc. bought a new stake in Pfizer in the first quarter worth $139,000. Finally, Clearwater Capital Advisors LLC bought a new stake in Pfizer in the first quarter worth $156,000. 69.03% of the stock is owned by institutional investors.

In related news, insider Alexander R. Mackenzie sold 25,642 shares of the business’s stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $39.51, for a total transaction of $1,013,115.42. Following the transaction, the insider now owns 127,954 shares in the company, valued at $5,055,462.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Loretta V. Cangialosi sold 26,814 shares of the business’s stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $40.16, for a total transaction of $1,076,850.24. Following the transaction, the vice president now owns 102,360 shares in the company, valued at approximately $4,110,777.60. The disclosure for this sale can be found here. Insiders have sold 234,096 shares of company stock worth $9,366,617 in the last quarter. 0.06% of the stock is owned by corporate insiders.



Shares of NYSE:PFE opened at $42.60 on Monday. The stock has a market cap of $253.59 billion, a PE ratio of 16.08, a PEG ratio of 2.18 and a beta of 0.96. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41. Pfizer Inc. has a 12 month low of $33.20 and a 12 month high of $45.81.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.74 by $0.07. The firm had revenue of $13.47 billion during the quarter, compared to the consensus estimate of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.19%. The ex-dividend date of this dividend is Thursday, November 8th. Pfizer’s dividend payout ratio is currently 51.32%.

Several research firms have weighed in on PFE. ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Tuesday, October 9th. Morningstar set a $46.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, October 9th. Independent Research set a $48.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Thursday, October 4th. Barclays set a $40.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Friday, October 19th. Finally, Cantor Fitzgerald set a $45.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Thursday, October 4th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $42.80.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Further Reading: Price to Earnings Ratio (PE), For Valuing Stocks

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply